Autolus Therapeutics plc
AUTL
$1.58
$0.106.42%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -224.80M | -227.78M | -238.13M | -220.66M | -270.23M |
| Total Depreciation and Amortization | 9.26M | 8.66M | 8.19M | 7.72M | 7.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 17.32M | -2.29M | 16.23M | 30.33M | 66.52M |
| Change in Net Operating Assets | -55.96M | -41.61M | -27.60M | -23.66M | 3.13M |
| Cash from Operations | -254.18M | -263.02M | -241.32M | -206.27M | -193.17M |
| Capital Expenditure | -31.04M | -36.22M | -29.79M | -22.08M | -12.44M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -280.63M | -320.59M | -423.78M | -372.48M | -- |
| Cash from Investing | -311.67M | -356.81M | -453.57M | -394.55M | -12.44M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 7.00K | 192.00K | 317.00K | 550.58M | 550.60M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 27.46M | 29.23M | 27.80M | 38.98M | 8.98M |
| Cash from Financing | 27.47M | 29.42M | 28.11M | 589.55M | 559.57M |
| Foreign Exchange rate Adjustments | -32.53M | 8.78M | 4.48M | -261.00K | 47.73M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -570.91M | -581.63M | -662.29M | -11.53M | 401.69M |